<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132690">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01734278</url>
  </required_header>
  <id_info>
    <org_study_id>OBSERVA</org_study_id>
    <nct_id>NCT01734278</nct_id>
  </id_info>
  <brief_title>Observational Post-Authorisation Safety Study of Asenapine (Sycrest)</brief_title>
  <acronym>OBSERVA</acronym>
  <official_title>An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Saad Shakir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Drug Safety Research Unit, Southampton, UK</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate the use and short term safety of
      Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United
      Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by
      the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the
      manufacturer of Sycrest.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The incidence of selected identified risks of asenapine in the mental health care trust setting</measure>
    <time_frame>12 weeks after asenapine is first prescribed</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Patients Prescribed Asenapine for Moderate to Severe Manic Episodes Associated With Bipolar I Disorder in Adults (or Off-label Use).</condition>
  <arm_group>
    <arm_group_label>Asenapine</arm_group_label>
    <description>Patients prescribed asenapine for any indication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is a non-interventional study.</description>
    <arm_group_label>Asenapine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients prescribed asenapine in a NHS Mental Health Trust in England.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients for whom a study questionnaire containing useful information has been
             returned

        Exclusion Criteria:

          -  Patients who do not provide consent

          -  Patients within selected institutions (for example prisons)

          -  Patients who commenced treatment between date of market launch (to be  confirmed) and
             study start

          -  Enrolled patients for whom both the baseline and 12-week questionnaires are returned
             blank (contain no clinical information)

          -  Enrolled patients for whom the psychiatrist, designated member of clinical care team,
             or study facilitator from the DSRU reports that the patient did not take or was never
             prescribed asenapine

          -  Enrolled patients for whom there is evidence to suggest duplication of patients

          -  Enrolled patients for whom informed written or verbal notification is received by
             DSRU indicating that they no longer wish to participate at any stage of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Felicity Mitchell, PhD</last_name>
    <phone>00442380019562</phone>
    <email>felicity.mitchell@dsru.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>South Staffordshire and Shropshire Healthcare NHS Foundation Trust</name>
      <address>
        <city>Stafford</city>
        <state>Staffordshire</state>
        <zip>ST16 3SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 8, 2013</lastchanged_date>
  <firstreceived_date>November 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Drug Safety Research Unit, Southampton, UK</investigator_affiliation>
    <investigator_full_name>Professor Saad Shakir</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
